Minocycline Base Polymorphs for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Minocycline base, a broad-spectrum antibiotic, has limited solubility and bioavailability in its amorphous form, making it challenging for effective pharmaceutical formulations, particularly for treating acne and rosacea.
Innovation Solution
Development of new crystalline forms, specifically Forms IV and V, with improved solubility profiles and favorable log P values, characterized by distinct X-ray powder diffraction patterns and thermogravimetric analysis, which can be prepared through dissolution in aliphatic ketones or suspension in 2-methyl tetrahydrofuran with specific temperature profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If minocycline base is used in amorphous form, then it has limited solubility, but it is easier to handle and formulate
Solution Approach 1:
The patent applies parameter changes by transforming minocycline base from amorphous to crystalline forms with specific polymorphic structures (Forms I, II, III, IV, V). Each crystalline form has distinct X-ray diffraction patterns and solubility characteristics. For example, Form IV shows peaks at 8.3, 13.46, 14.1, 21.3, 16.62° 2θ and exhibits improved solubility compared to amorphous form, while maintaining crystalline stability for easier handling and formulation.
Solution Approach 2:
The patent creates composite crystalline structures by developing multiple polymorphic forms of minocycline base, each with unique molecular packing arrangements. These crystalline forms represent composite states of the same chemical compound, where the molecular lattice structure is reorganized to achieve both improved solubility and formulation stability simultaneously.
2Quantity of substance
If new crystalline forms IV and V are developed, then solubility and bioavailability are improved, but the preparation process becomes more complex
Solution Approach 1:
The patent utilizes phase transitions by employing specific dissolution and precipitation conditions to transform minocycline base into desired crystalline forms. For example, Form IV is prepared by dissolving minocycline base in aliphatic ketones (such as acetone or methyl ethyl ketone) at elevated temperatures, then cooling the solution to induce crystallization. Form V is obtained by suspending minocycline base in 2-methyl THF and applying thermocycling temperature profiles. These controlled phase transitions enable reproducible generation of crystalline forms with improved solubility.
Solution Approach 2:
The patent applies parameter changes by optimizing dissolution/precipitation temperatures, solvent types, and stirring durations to achieve high yields of desired crystalline forms. For Form IV, dissolution occurs at 20-25°C with stirring for at least 30 minutes, followed by isolation. For Form V, thermocycling between 40°C and 5°C is applied to the suspension in 2-methyl THF. These parameter optimizations simplify the preparation process while ensuring reproducible results.
3Stability of the object's composition
If crystalline forms are used instead of amorphous form, then stability is improved, but solubility is reduced
Solution Approach 1:
The patent resolves this contradiction by discovering and characterizing multiple crystalline polymorphic forms (I, II, III, IV, V) of minocycline base, each with distinct stability-solubility profiles. The newer forms (IV and V) were specifically identified to provide both enhanced stability compared to amorphous form and improved solubility compared to earlier crystalline forms. Form IV exhibits peaks at 8.3, 13.46, 14.1, 21.3, 16.62° 2θ and Form V at 5.34, 16.74, 21.06, 23.02, 22.26° 2θ, representing optimized crystalline structures that balance stability and solubility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms enhance bioavailability and ease of formulation, offering improved solubility and stability, as evidenced by enhanced solubility measurements and log P values compared to previous forms, facilitating more effective antibacterial and anti-inflammatory pharmaceutical compositions.
Implementation Method 1
characterized by an X-ray powder diffraction pattern having peaks at 8.3; 13.46; 14.1, 21.3; 16.62 ± 0.2° 2θ
Implementation Method 2
X-ray powder diffraction pattern having peaks at 7.06, 8.3, 10.3, 11.18, 13.46, 14.1, 14.94, 16.62, 20.62, 21.3, ± 0.2° 2θ
Implementation Method 3
Crystalline minocycline base form IV according to the invention preferably shows an endotherm at 146°C from the STDA signal of a TGA analysis
Implementation Method 4
comprising dissolving minocycline base in an aliphatic ketone having 8 carbon atoms or less, or 6 carbon atoms or less, followed by the precipitation of, and optionally isolation of, form IV
Implementation Method 5
followed by the precipitation of, and optionally isolation of, form IV
Implementation Method 6
suspending minocycline base in 2-methyl tetrahydrofuran (THF) and applying a thermocycling temperature profile for crystallization
Implementation Method 7
the thermocycling temperature profile comprises heating the suspension three times up to a temperature of about 40°C (+/- 5 °C) and cooling each time to about 5 °C (+/- 5 °C)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention concerns new forms of crystalline minocycline base. In particular, two new crystalline polymorphic forms, designated Form IV and Form V of minocycline base are provided. These are characterized by XRD, FTIR and TGA. Processes for preparing the new polymorphic forms and their use in pharmaceutical compositions are also provided. Form IV and form V are prepared by dissolving and/or suspending minocycline base in an organic solvent followed by crystallization.